Add BrightSurf on Google Email

NRG Oncology trial does not improve overall survival, but shows improvements in several clinical outcomes for men with intermediate-risk prostate cancer

The study found that dose-escalated radiotherapy with short-term androgen deprivation therapy improved rates of biochemical failure, distant metastases, and prostate cancer-specific mortality. However, the trial did not meet its primary endpoint of improving overall survival for men with intermediate-risk prostate cancer.

SourceNRG Oncology·JournalJournal of Clinical Oncology·DateApr 27, 2023

Patient-reported outcomes from an NRG Oncology study of androgen deprivation therapy with dose-escalated radiotherapy for intermediate-risk prostate cancer show no clinically meaningful differences in scores at one year post-treatment

A recent study published in Journal of Clinical Oncology found that dose-escalated radiotherapy with short-term androgen deprivation therapy showed no significant impact on urinary or bowel quality of life for men with intermediate-risk prostate cancer. However, the treatment did significantly decrease hormone and sexual quality of lif...

SourceNRG Oncology·JournalJournal of Clinical Oncology·DateApr 27, 2023

Can a healthy diet prevent prostate cancer?

A study of 15,296 men found that a healthy Mediterranean or Prudent diet had no impact on prostate cancer risk, while an unhealthy Western diet may increase the risk of aggressive tumors. The findings suggest avoiding Western-style diet products and adopting Mediterranean diet habits could help prevent aggressive prostate cancer.

SourceWiley·JournalBJU International·DateApr 19, 2023

Genome-wide CRISPR screens identify PARP inhibitor sensitivity and resistance in prostate cancer

A recent study identified novel genes that influence PARP inhibitor response in prostate cancer, including MMS22L and RNASEH2B. The research found that loss of CHEK2, a previously approved biomarker, confers resistance to PARP inhibition, highlighting the need for comprehensive genomic analysis to improve treatment decisions.

SourceBrigham and Women's Hospital·JournalNature Communications·TypeExperimental study·DateApr 4, 2023

Delaying treatment for localised prostate cancer does not increase mortality risk, trial shows

The ProtecT trial found that active monitoring of prostate cancer has the same high survival rates after 15 years as radiotherapy or surgery. Men on active monitoring were more likely to see their cancer progress, but this didn't reduce their likelihood of survival.

SourceEuropean Association of Urology·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateMar 11, 2023

New research in JNCCN highlights the negative impact of continued exclusion of racial groups from research on cancer genomics

A recent study published in JNCCN found that the lack of genomic research for people with African ancestry is hindering efforts to reduce disparities in prostate cancer outcomes. The researchers evaluated molecular genetic results for 113 Black South African men diagnosed with advanced prostate cancer, identifying 17 pathogenic and pot...

SourceNational Comprehensive Cancer Network·JournalJournal of the National Comprehensive Cancer Network·DateMar 10, 2023

Long-term exposure to nitrate in drinking water may be a risk factor for prostate cancer

A study published in Environmental Health Perspectives found that long-term exposure to nitrate in drinking water may increase the risk of prostate cancer, especially among younger men and those with aggressive tumors. Eating a diet rich in fiber, fruits, and vegetables can help mitigate this effect.

SourceBarcelona Institute for Global Health (ISGlobal)·JournalEnvironmental Health Perspectives·TypeRandomized controlled/clinical trial·DateMar 8, 2023

Death rates from lung cancer will fall overall in the EU and UK in 2023, but rise among women in France, Italy and Spain

Lung cancer death rates are projected to decrease overall in the EU and UK in 2023, however, a concerning trend is observed among women in France, Italy, and Spain. Meanwhile, pancreatic cancer death rates are forecasted to rise among women due to continued smoking habits.

SourceEuropean Society for Medical Oncology·JournalAnnals of Oncology·TypeObservational study·DateMar 5, 2023

Newly identified personalized immunotherapy combination treats an aggressive form of advanced prostate cancer

Researchers discovered a new personalized immunotherapy combination that treats aggressive forms of advanced prostate cancer. By blocking PD-1-expressing macrophages and Wnt/β-catenin pathway activation, the therapy significantly improves response rates in PTEN-deficient cancers.

SourceUniversity of Chicago Medical Center·JournalClinical Cancer Research·TypeExperimental study·DateMar 2, 2023

Study reinforces potential use of zika virus to combat prostate cancer but points to possible side-effect

Researchers analyzed zika virus effects on tumor cells and healthy cells, discovering its potential to treat prostate cancer but also triggering a persistent inflammatory process that damages the male reproductive system. The study's findings suggest long-term treatment could lead to recurrence of prostate cancer.

SourceFundação de Amparo à Pesquisa do Estado de São Paulo·JournalJournal of Proteome Research·DateMar 1, 2023

New mathematical model shows promising results for prostate cancer treatment

A new mathematical model has been developed to optimize treatment for prostate cancer, showing promising results in eliminating cancer cells. The model explores different therapeutic strategies, including single drugs and drug combinations, and suggests that alternating therapies could significantly improve cancer treatment.

SourceUniversity of Portsmouth·JournalMathematical Biosciences·TypeComputational simulation/modeling·DateMar 1, 2023

Moffitt researchers develop tool to measure patient health and well-being after radionuclide therapy

Researchers developed the Functional Assessment of Cancer Therapy – Radionuclide Therapy (FACT-RNT) questionnaire to identify key symptoms and side effects associated with radionuclide therapy. The tool aims to improve patient-centered care and guide treatment decisions for prostate cancer patients.

SourceH. Lee Moffitt Cancer Center & Research Institute·JournalJournal of Nuclear Medicine·TypeObservational study·DateJan 19, 2023

New University Hospitals Seidman Cancer Center study demonstrates the critical importance of social determinants of health when evaluating the association of race and cancer outcomes

A new study by University Hospitals Seidman Cancer Center demonstrates that social determinants of health, not just race, significantly influence prostate cancer outcomes. The research, published in JAMA Network Open, found that accounting for social determinants reduced racial disparities in mortality rates.

SourceUniversity Hospitals Cleveland Medical Center·JournalJAMA·TypeMeta-analysis·DateJan 18, 2023

MRI-guided radiotherapy produces fewer side effects and better quality of life for patients with localized prostate cancer

A new study found that MRI-guided radiotherapy is more effective than CT-guided therapy in reducing side effects and improving quality of life for patients with localized prostate cancer. The trial involved 154 patients, who experienced fewer toxicities and better outcomes when treated with MRI guidance.

SourceUniversity of California - Los Angeles Health Sciences·JournalJAMA Oncology·TypeRandomized controlled/clinical trial·DateJan 12, 2023

American Cancer Society releases latest cancer statistics, launches initiative to address prostate cancer resurgence and disparities

The American Cancer Society released its annual report on cancer facts and trends, showing a 33% drop in overall cancer mortality since 1991. However, prostate cancer incidence increased by 3% per year from 2014 to 2019, with advanced-stage disease diagnoses rising by 4-5% annually.

SourceAmerican Cancer Society·JournalCA A Cancer Journal for Clinicians·DateJan 12, 2023

Study finds providers use prostate cancer screening tests, even when they provide little value to patients

A study by Wake Forest University School of Medicine found that primary care providers frequently order prostate cancer screening tests, even when they provide little value to patients. The research team analyzed data from the National Ambulatory Medicare Care Survey and found a significant increase in low-value screenings, such as PSA...

SourceAtrium Health Wake Forest Baptist·JournalThe Journal of the American Board of Family Medicine·DateJan 4, 2023

Exercise is medicine for cancer and every dose counts - even in late stages in the disease

A new study from Edith Cowan University found that a single bout of exercise can significantly suppress tumour growth in people with late-stage prostate cancer. The researchers observed increased levels of anti-cancer myokines after high-intensity exercise, which helped fight cancerous cells and stimulated anti-cancer processes.

SourceEdith Cowan University·JournalProstate Cancer and Prostatic Diseases·TypeObservational study·DateDec 13, 2022

Artificial Intelligence in Health: USC Researchers receive $10.5 million to develop cutting edge machine learning approaches in cancer research

The National Cancer Institute awards $10.5 million to USC's Division of Biostatistics to develop statistical methods for uncovering new risk factors associated with cancer by integrating large volumes of health, genomic, and exposure data. The project aims to provide new insights into complex biological processes and discoveries of nov...